Online citations, reference lists, and bibliographies.

Validation That Metabolic Tumor Volume Predicts Outcome In Head-and-neck Cancer.

Chad Tang, James D Murphy, Brian Khong, Trang H. La, Christina S. Kong, Nancy Fischbein, Alexander Dimitrios Colevas, Andrei Iagaru, Edward E Graves, Billy W. Loo, Quynh-Thu Le
Published 2012 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE We have previously reported that metabolic tumor volume (MTV) obtained from pretreatment (18)F-fluorodeoxydeglucose positron emission tomography (FDG PET)/ computed tomography (CT) predicted outcome in patients with head-and-neck cancer (HNC). The purpose of this study was to validate these results on an independent dataset, determine whether the primary tumor or nodal MTV drives this correlation, and explore the interaction with p16(INK4a) status as a surrogate marker for human papillomavirus (HPV). METHODS AND MATERIALS The validation dataset in this study included 83 patients with squamous cell HNC who had a FDG PET/CT scan before receiving definitive radiotherapy. MTV and maximum standardized uptake value (SUV(max)) were calculated for the primary tumor, the involved nodes, and the combination of both. The primary endpoint was to validate that MTV predicted progression-free survival and overall survival. Secondary analyses included determining the prognostic utility of primary tumor vs. nodal MTV. RESULTS Similarly to our prior findings, an increase in total MTV of 17 cm(3) (difference between the 75th and 25th percentiles) was associated with a 2.1-fold increase in the risk of disease progression (p = 0.0002) and a 2.0-fold increase in the risk of death (p = 0.0048). SUV(max) was not associated with either outcome. Primary tumor MTV predicted progression-free (hazard ratio [HR] = 1.94; p < 0.0001) and overall (HR = 1.57; p < 0.0001) survival, whereas nodal MTV did not. In addition, MTV predicted progression-free (HR = 4.23; p < 0.0001) and overall (HR = 3.21; p = 0.0029) survival in patients with p16(INK4a)-positive oropharyngeal cancer. CONCLUSIONS This study validates our previous findings that MTV independently predicts outcomes in HNC. MTV should be considered as a potential risk-stratifying biomarker in future studies of HNC.
This paper references
10.1056/NEJMoa0912217
Human papillomavirus and survival of patients with oropharyngeal cancer.
K Kian Ang (2010)
10.1002/hed.21406
Intensity-modulated radiotherapy for locally advanced cancers of the larynx and hypopharynx.
Megan E. Daly (2011)
10.1016/j.radonc.2009.04.014
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.
Jean-Pierre Pignon (2009)
10.1016/S1470-2045(10)70017-6
HPV-associated head and neck cancer: a virus-related cancer epidemic.
Shanthi Marur (2010)
10.1148/radiol.2331030660
Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen.
Jean-François Daisne (2004)
10.1002/jbm.a.31888
Platelet and endothelial adhesion on fluorosurfactant polymers designed for vascular graft modification.
Chad Tang (2009)
10.1214/aos/1176350951
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
R. Gray (1988)
10.1200/JCO.2006.08.2305
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.
Malik E Juweid (2007)
10.1007/s00432-009-0729-7
Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma
Peng Xie (2009)
10.1016/j.ijrobp.2009.04.006
Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure.
Megan E. Daly (2010)
10.1016/j.ijrobp.2008.10.060
Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer.
Trang H. La (2009)
10.1200/JCO.2008.19.3300
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer.
Benjamin J. Moeller (2009)
10.1200/JCO.2010.29.2904
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.
Danny Rischin (2010)
10.1016/j.ijrobp.2009.02.015
The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas.
Christina S. Kong (2009)
10.1016/j.ijrobp.2010.01.057
Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer.
James D Murphy (2011)
10.1080/02841850802027034
Impact of fdg-pet/ct fused imaging on tumor volume assessment of head-and-neck squamous cell carcinoma: intermethod and interobserver variations
Ryuji Murakami (2008)



This paper is referenced by
10.1016/J.MEDNUC.2015.06.001
PET/CT in radiotherapy planning in head and neck cancers
Ana María García Vicente (2015)
10.4103/ijmpo.ijmpo_253_17
Role of pretreatment fluorodeoxyglucose positron emission tomography quantitative parameters in prognostication of head-and-neck squamous cell carcinoma
Narayana Subramaniam (2019)
10.1016/j.cpet.2012.06.003
The Application of FDG-PET as Prognostic Indicators in Head and Neck Squamous Cell Carcinoma.
Farzan Siddiqui (2012)
10.1186/s40463-014-0033-7
Metabolic tumour volume as a prognostic factor for oral cavity squamous cell carcinoma treated with primary surgery
Han Zhang (2014)
10.1007/s10266-018-0379-9
Correlation between the malignancy and prognosis of oral squamous cell carcinoma in the maximum standardized uptake value
On Hasegawa (2018)
10.25148/etd.FI12121004
Positron Emission Tomography (PET) Tumor Segmentation and Quantification: Development of New Algorithms
Ruchir N. Bhatt (2012)
10.1007/s00259-013-2618-1
Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma
Ronan Abgral (2013)
10.1007/s13193-018-0840-9
Organ Preservation Protocols in T4 Laryngeal Cancer: a Review of the Literature
Narayana Subramaniam (2018)
10.2214/AJR.14.12497
Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma.
Krishna C Alluri (2014)
10.4103/0973-1482.137968
Prognostic significance and predictive performance of volume-based parameters of F-18 FDG PET/CT in squamous cell head and neck cancers.
Sait Sağer (2014)
10.1016/j.oraloncology.2015.09.001
Pre-treatment tumor-specific growth rate as a temporal biomarker that predicts treatment failure and improves risk stratification for oropharyngeal cancer.
Colin T. Murphy (2015)
10.4103/bbrj.bbrj_75_18
Prognostic value of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan volumetric parameters in head-and-neck cancer patients after treatment
Mehrdad Bakhshyesh Karam (2018)
10.1016/j.oraloncology.2014.02.001
Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer.
Jeffrey M. Vainshtein (2014)
10.3389/fonc.2019.01118
Predictive Values of MRI and PET Derived Quantitative Parameters for Patterns of Failure in Both p16+ and p16– High Risk Head and Neck Cancer
Yue Cao (2019)
10.1177/0003489419834312
Clinical Utility of Pretreatment and 3-Month 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Standardized Uptake Value in Predicting and Assessing Recurrence in T3-T4 Laryngeal Carcinoma Treated With Definitive Radiation
Zachary Mayo (2019)
10.1016/j.canlet.2014.07.042
PET/CT imaging-guided dose painting in radiation therapy.
Xiaorong Shi (2014)
10.1007/s00330-016-4276-8
Dynamic contrast-enhanced MRI, diffusion-weighted MRI and 18F-FDG PET/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation
Shu-Hang Ng (2016)
Radiotherapy treatment planning based on functional PET/CT imaging data
Daniela Thorwarth (2012)
Radiothérapie adaptative morphologique et métabolique des cancers ORL
Joël Castelli (2017)
10.4329/wjr.v6.i6.238
Application of fluorodeoxyglucose positron emission tomography in the management of head and neck cancers.
Farzan Siddiqui (2014)
Oesophagogastric cancer: exploring the way to an individual approach
Jurriën Stiekema (2015)
10.1111/1754-9485.12081
Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: value of FDG volumetric imaging parameters.
Jielin Yu (2014)
10.1016/j.radonc.2019.05.019
The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status.
Jon M Moan (2019)
10.1002/lary.27173
FDG-PET metabolic tumor parameters for the reirradiation of recurrent head and neck cancer.
Maria Agudelo Velez (2018)
10.1053/j.semnuclmed.2012.04.005
The evolving role of positron emission tomography-computed tomography in organ-preserving treatment of head and neck cancer.
Madhur Garg (2012)
10.1002/hed.23784
Prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography/CT volume-based parameters in patients with oropharyngeal squamous cell carcinoma with known p16 and p53 status.
Masahiro Kikuchi (2015)
10.21037/tro.2018.01.08
Prognostic effects of the metabolic tumor volume and total lesion glycolysis in patients with advanced squamous cell carcinoma of head and neck
He-Yuan Hsieh (2018)
10.1007/978-3-319-27601-4_13
Imaging of head and neck cancers
Taha S. Meraj (2016)
10.1016/j.ijrobp.2019.03.036
Integrating Tumor and Nodal Imaging Characteristics at Baseline and Mid-Treatment Computed Tomography Scans to Predict Distant Metastasis in Oropharyngeal Cancer Treated With Concurrent Chemoradiotherapy.
Jia Wu (2019)
Role of Pre -Treatment FDG PET Quantitative Parameters in Prognostication of Head and Neck Squamous Cell Carcinoma-A Review
Narayana Subramaniam (2017)
10.2217/IIM.12.60
FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma.
Vasavi Paidpally (2012)
10.1007/174_2013_934
Head and Neck Squamous Cell Cancer
Carsten Nieder (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar